

Patient: Doe, Jane Date of Birth: Feb 28, 2000 Sex: Female	Physician: Dr. Amy Miller NPI #:999999999 Practice: Sample Philadelphia, PA	Date Collected: Feb 24, 2019 Date Received: Feb 25, 2019 Date Processed: Feb 25, 2019 Specimen type/Source: Swab Sample ID: utiabxr1
--	--	--

1. About This Report

This UTI Assay is a urinary tract infection screen that consists of clinical, molecular tests for microorganisms implicated in UTIs.

2. Molecular Diagnostic Results

Urinary Tract Infection		STI			
-	<i>A. baumannii</i>	Negative	-	<i>C. trachomatis</i>	Negative
-	<i>C. albicans</i>	Negative	-	<i>N. gonorrhoeae</i>	Negative
-	<i>C. freundii</i>	Negative	-	<i>C. albicans</i>	Negative
-	<i>E. aerogenes</i>	Negative	-	<i>C. glabrata</i>	Negative
-	<i>E. cloacae</i>	Negative	-	<i>S. agalactiae</i>	Negative
H	<i>E. coli</i>	Positive			
H	<i>E. faecalis</i>	Positive			
-	<i>E. faecium</i>	Negative			
M	<i>K. oxytoca</i>	Positive			
-	<i>K. pneumoniae</i>	Negative			
-	<i>M. morgani</i>	Negative			
-	<i>P. aeruginosa</i>	Negative			
-	<i>P. mirabilis</i>	Negative			
-	<i>P. stuartii</i>	Negative			
-	<i>P. vulgaris</i>	Negative			
-	<i>S. agalactiae</i>	Negative			
M	<i>S. aureus</i>	Positive			
-	<i>S. saprophyticus</i>	Negative			

3. Antibiotic Treatment Options

The following table shows common treatment options for organisms assayed as present in this sample, combined with any positive or negative assayed resistance markers. "T" indicates a treatment option; "T:R" indicates a treatment option that may be affected by the detected resistance marker(s).

utiabxr1 - Doe, Jane - Reported Feb 28, 2019 - DRAFT

The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding use of prescribed medications must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient's medical history, and current treatment regimen.

Abundance	Resistances				
	<i>E. coli</i>	<i>E. faecalis</i>	<i>K. oxytoca</i>	<i>S. aureus</i>	
	H	H	M	M	
† ceftriaxone (AmpC)	-	T:R	-	-	ampC
fosfomycin (Broad-spectrum antibiotic)	S	-	-	-	Not assayed
ampicillin (Extended-Spectrum-Beta lactam)	-	S	-	S	Not assayed
amoxicillin (Extended-Spectrum-Beta lactam)	-	S	-	-	Not assayed
gentamicin (Glycoside)	-	S	-	-	Not assayed
streptomycin (Glycoside)	-	S	-	S	Not assayed
penicillin g (Narrow-Spectrum-Beta lactam)	-	-	-	S	Not assayed
nitrofurantoin (Nitrofurans)	S	S	S	S	Not assayed
linezolid (Oxazolidinone)	-	S	-	-	Not assayed
daptomycin (Peptide)	-	S	-	-	Not assayed
trimethoprim (Pyrimidines)	S	-	-	-	Not assayed
ciprofloxacin (Quinolone and fluoroquinolone)	-	-	S	-	Negative
levofloxacin (Quinolone and fluoroquinolone)	-	-	S	-	Negative
trimethoprim/sulfamethoxazole (Sulfonamides)	S	-	S	-	Not assayed
tigecycline (Tetracyclines)	-	S	-	S	Not assayed
vancomycin (Vancomycin)	-	S	-	S	Negative

S = Consider alternate treatment due to detected resistance marker(s).

utiabxr1 - Doe, Jane - Reported Feb 28, 2019 - DRAFT


The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding use of prescribed medications must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient's medical history, and current treatment regimen.

UTI Report

- -

Antibiotic Resistance

Assayed Resistance Markers



SAMPLE

-
1. AmpC resistance
 2. Macrolide resistance
 3. Methicillin resistance
 4. tetracycline-resistant ribosomal protection protein

utiabxr1 - Doe, Jane - Reported Feb 28, 2019 - DRAFT

The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding use of prescribed medications must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient's medical history, and current treatment regimen.

- -

UTI Report

4. Microorganisms Tested

Organism/Assay	ctMean	Presence
<i>A. baumannii</i>	N/A	Not Detected
<i>ampC</i> (<i>AmpC</i> resistance)	14.123	Detected
<i>blaOXA-48</i>	N/A	Not Detected
<i>Broad-range 16s</i>	16.519	Detected
<i>C. albicans</i>	N/A	Not Detected
<i>C. freundii</i>	N/A	Not Detected
<i>C. glabrata</i>	29.501	Not Detected
<i>C. trachomatis</i>	N/A	Not Detected
<i>E. aerogenes</i>	N/A	Not Detected
<i>E. cloacae</i>	N/A	Not Detected
<i>E. coli</i>	14.123	Detected
<i>E. faecalis</i>	14.123	Detected
<i>E. faecium</i>	N/A	Not Detected
<i>ErmA</i>	N/A	Not Detected
<i>ErmB</i> (<i>Macrolide</i> resistance)	23.832	Detected
<i>ermC</i>	30.339	Not Detected
<i>K. oxytoca</i>	22.123	Detected
<i>K. pneumoniae</i>	N/A	Not Detected
<i>KPC</i>	N/A	Not Detected
<i>M. morgani</i>	N/A	Not Detected
<i>mecA</i> (<i>Methicillin</i> resistance)	29.193	Detected
<i>N. gonorrhoeae</i>	N/A	Not Detected
<i>P. aeruginosa</i>	N/A	Not Detected
<i>P. mirabilis</i>	N/A	Not Detected
<i>P. stuartii</i>	N/A	Not Detected
<i>P. vulgaris</i>	N/A	Not Detected
<i>QnrA</i>	N/A	Not

SAMPLE

utiabxr1 - Doe, Jane - Reported Feb 28, 2019 - DRAFT

The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding use of prescribed medications must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient's medical history, and current treatment regimen.

UTI Report

<i>QnrB</i>	N/A	Detected
		Not Detected
<i>S. agalactiae</i>	N/A	Not Detected
		Detected
<i>S. aureus</i>	22.123	Detected
<i>S. saprophyticus</i>	N/A	Not Detected
		Detected
<i>tetM</i> (tetracycline-resistant ribosomal protection protein)	24.079	Detected
<i>vanA1</i>	N/A	Not Detected
		Detected
<i>vanA2</i>	N/A	Not Detected
		Detected
<i>vanB</i>	N/A	Not Detected
		Detected
<i>vanC1</i>	N/A	Not Detected
		Detected
<i>Xeno</i>	23.555	Detected

Limitation: An absence of detection does not imply the absence of microorganisms other than those listed or does not exclude the possibility that the target sequence is present below the limit of detection. The UTI Report does not take into consideration patient history, drug-drug interactions, drug sensitivity, and/or allergies. It is the responsibility of the physician to determine appropriate drug and dosing choices based on all available data.

Methodology: Array based assays simultaneously detect a wide array of bacteria, viruses, and parasites at analytical sensitivity

and specificity >99% Administration. The FDA has determined that such approval is not necessary, provided that the laboratory

both (1) maintains its good standing as a clinical testing laboratory with all mandatory accrediting bodies, and (2) continually demonstrates that its testing protocols and procedures achieve a high degree of analytical accuracy.

Laboratory Certification: CLIA # SAMPLE

Laboratory Director: John Doe, M D.

utiabxr1 - Doe, Jane - Reported Feb 28, 2019 - DRAFT

The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding use of prescribed medications must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient's medical history, and current treatment regimen.